Skip to content
Project Directory
  • Français
Donate Now
  • Français
  • About
    • What We Do
    • Leadership
    • Team
    • Publications
    • Careers
  • Diseases/Disorders
    • One Brain
    • ALS
    • Alzheimer’s
    • Autism
    • Brain Cancer
    • Brain Injury
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • Other
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
  • Ways To Give
    • Your Impact
    • How You Can Help
    • Events

Funded Grants

Back to results

Gold and BBB Opening in ALS (The GOALS Trial): A Phase 2a, Open-label, Single-arm Clinical Trial of Oral CNM-Au8 Coupled with Primary Motor Cortex Blood Brain Barrier Opening Using Transcranial MR-guided Focused Ultrasound in Amyotrophic Lateral Sclerosis

Project Overview

Rationale: Mitochondrial dysfunction has been identified as a contributing factor for bioenergetic dysregulation and neurodegeneration in the motor cortex and spinal cord of patients with ALS. CNM-Au8 is an investigational compound designed to promote biocatalytic activity and is effective in improving mitochondrial function and survival in preclinical ALS models.  Oral CNM-Au8 is currently being tested in phase-2 and Healey platform clinical trials in ALS patients; however, the therapeutic effect of CNM-Au8 is expected to be suboptimal due to limited permeability across the blood-spinal cord and blood brain barrier (BBB). Considering the importance of the motor cortex in contributing to ALS pathogenesis, to achieve therapeutic success it is essential to optimize bioavailability of CNM-Au8 in degenerating cortical motor neurons. Using the non-invasive technique of MR-guided focused ultrasound (MRgFUS) which recently demonstrated safety in ALS (Abrahao et al), BBB permeability can be enhanced to increase drug delivery to the targeted motor cortex.

Objective & Specific Aims: We propose to couple oral administration of CNM-Au8 with BBB opening in the motor cortex to increase bioavailability and bioenergetic effects in an open-label, dose-ascending, safety trial. This study will evaluate the following specific aims: 1) the safety and feasibility of oral CNM-Au8 30 or 60 mg administration over 8 weeks in conjunction with a single primary motor cortex MRgFUS BBB opening procedure in 10 volunteers with ALS; 2) target engagement and bioenergetic pharmacodynamics of enhanced motor cortex delivery of CNM-Au8 with MRgFUS, measured by 31P magnetic resonance spectroscopy (MRS) in the treated hemisphere, normalized to the contralateral side; 3) pharmacokinetics and exploratory pharmacodynamic signals of enhanced CNM-Au8 CNS delivery as measured by changes in upper motor neuron neurophysiology using transcranial magnetic stimulation, serum and CSF metabolomics and light chain neurofilament levels, and advanced neuroimaging with MRS (in collaboration with the Canada-wide CAPTURE study).

Significance: CNM-Au8 improves mitochondrial function by modulating biocatalytic activity and thereby improves motor neuron health. Its low bioavailability secondary to limited BBB permeability is a critical limitation, which can be remedied by coupling oral CNM-Au8 administration with MRgFUS targeted BBB opening. This study will demonstrate the safety, enhanced delivery and target engagement of CNM-Au8 using MRgFUS. Importantly, this is the first study to use MRgFUS to enhance the delivery of a therapeutic across the BBB in the ALS population and is the essential next step for establishing a non-invasive delivery platform for a variety of ALS therapeutics.

Principal Investigator

Agessandro Abrahao , Sunnybrook Health Sciences Centre, University of Toronto

Team Members

Lorne Zinman, Sunnybrook Research Institute

Nir Lipsman, Sunnybrook Research Institute

Kullervo Hynynen, Sunnybrook Research Institute

Simon Graham, Sunnybrook Research Institute

Jamie Near, McGill University

Sanjay Kalra, University of Alberta

Kelvin Jones, University of Alberta

Isabelle Aubert, Sunnybrook Research Institute

Sonam Dubey, University of Toronto

Partners and Donors

ALS Canada

Project Ongoing

Gold and BBB Opening in ALS (The GOALS Trial): A Phase 2a, Open-label, Single-arm Clinical Trial of Oral CNM-Au8 Coupled with Primary Motor Cortex Blood Brain Barrier Opening Using Transcranial MR-guided Focused Ultrasound in Amyotrophic Lateral Sclerosis

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    ALS

  • Competition

    ALS Canada - Brain Canada Discovery Grants

  • Province

    Ontario

  • Start Date

    2022

  • Total Grant Amount

    $125,000

  • Health Canada Contribution

    $62,500

Contact Us

1200 McGill College Avenue
Suite 1600, Montreal, Quebec
H3B 4G7

+1 (514) 989-2989 info@braincanada.ca

Playing with Marbles Podcast

Join us and take a journey to the real last great frontier – the brain.

Listen

Subscribe to Brain News

Receive our monthly electronic newsletter with updates on funded projects, upcoming events and breakthroughs in brain research.

Sign up

© 2023 Brain Canada Foundation

Registration number: 89105 2094 RR0001

  • Terms and Conditions
  • Privacy Policy

Design by Field Trip & Co